Lars B. Abrahmsen

Karolinska Institute Science Park
Solna, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Journal: Cell death & disease

Published: August 03, 2022

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Journal: Cancers

Published: July 12, 2022

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Journal: Cell death & disease

Published: May 06, 2021

Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).

Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).

Journal: Nature communications

Published: January 21, 2021

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.

Journal: EMBO molecular medicine

Published: May 07, 2019

Restoration of conformation of mutant p53.

Restoration of conformation of mutant p53.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 21, 2018

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Journal: Nature communications

Published: November 15, 2016

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Journal: Frontiers in oncology

Published: December 22, 2015

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: July 11, 2015

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: November 20, 2014

Early implementation of QbD in biopharmaceutical development: a practical example.

Early implementation of QbD in biopharmaceutical development: a practical example.

Journal: BioMed research international

Published: October 31, 2014

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism.

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism.

Journal: Oncotarget

Published: October 01, 2014

Showing 1-12 of 21

Last Updated: 09/26/2026